据创鉴汇不完全统计,8月25日至8月31日全球生物制药领域共披露21起交易事件,潜在交易总额超46亿美元。其中,6笔潜在交易总额超1亿美元,1笔达10亿美元量级。标的多为小分子药物、抗体、RNA疗法及AI技术平台。上周最大规模的一笔交易来自CNS领域,艾伯维(AbbVie)以最高12亿美元收购Gilgamesh Pharmaceuticals的核心资产bretisilocin(GM-2505)。该...
Source Link据创鉴汇不完全统计,8月25日至8月31日全球生物制药领域共披露21起交易事件,潜在交易总额超46亿美元。其中,6笔潜在交易总额超1亿美元,1笔达10亿美元量级。标的多为小分子药物、抗体、RNA疗法及AI技术平台。上周最大规模的一笔交易来自CNS领域,艾伯维(AbbVie)以最高12亿美元收购Gilgamesh Pharmaceuticals的核心资产bretisilocin(GM-2505)。该...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.